SCHEMBL3473291

SCHEMBL3473291

COCCCN1CCN(C(=O)c2cc(-c3ccc(-c4cccc(S(C)(=O)=O)c4)s3)n(-c3ccccc3Cl)n2)CC1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 7/20 0.67
NR1H2 P55055 7/20 0.67
NR1H3 Q13133 7/20 0.67
CYP2C9 P11712 2/20 0.38
CYP2C19 P33261 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
TACR2 P21452 1/20 0.38
TACR1 P25103 1/20 0.38
TACR3 P29371 1/20 0.38
DRD2 P14416 4/20 0.38
HTR2A P28223 2/20 0.38
SMPD1 P17405 1/20 0.38
PTGS2 P35354 4/20 0.35
SLC16A3 O15427 1/20 0.35
SLC16A1 P53985 1/20 0.35
MCTS1 Q9ULC4 1/20 0.35
PTGS1 P23219 2/20 0.35
DRD3 P35462 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3472992 0.98 RXRA (0.66) RXRANR1H2NR1H3CYP2C9CYP2C19
SCHEMBL3472946 0.96 RXRA (0.69) RXRANR1H2NR1H3CYP2C9CYP2C19
SCHEMBL3474285 0.91 RXRA (0.64) RXRANR1H2NR1H3CYP2C9CYP2C19
SCHEMBL3473491 0.91 RXRA (0.68) RXRANR1H2NR1H3CYP2C9CYP2C19
SCHEMBL3473985 0.91 RXRA (0.64) RXRANR1H2NR1H3CYP2C9CYP2C19
SCHEMBL3472950 0.91 RXRA (0.63) RXRANR1H2NR1H3CYP2C9CYP2C19
SCHEMBL3472803 0.91 RXRA (0.63) RXRANR1H2NR1H3CYP2C9CYP2C19
SCHEMBL3473514 0.90 RXRA (0.67) RXRANR1H2NR1H3CYP2C9CYP2C19
SCHEMBL3471607 0.90 RXRA (0.67) RXRANR1H2NR1H3CYP2C9CYP2C19
SCHEMBL3473298 0.90 RXRA (0.62) RXRANR1H2NR1H3DRD2HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US claimed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
WO-2007002559-A1 PYRAZOLE BASED LXR MODULATORS EXELIXIS, INC. (US) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331295-A1 MODULATORS OF LXR NR1H2, NR1H3, NR1H4 RXRA 18/4885NR1H2 1/4885NR1H3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.